Table 2.
Clinicopathologic features and PTHrP expression
| PTHrP positive | PTHrP negative | χ2 | P value | |
|---|---|---|---|---|
| No. (%) | No. (%) | |||
| Age | ||||
| ≤55 | 146 (53.9 %) | 121 (53.5 %) | 0.006 | 0.941 |
| >55 | 125 (46.1 %) | 105 (46.5 %) | ||
| Tumor size | ||||
| ≤2 cm | 133 (49.1 %) | 145 (64.2 %) | 11.372 | 0.001 |
| >2 cm | 138 (50.9 %) | 81 (35.8 %) | ||
| Skin involvementa | ||||
| No | 223 (82.3 %) | 196 (86.7 %) | 1.834 | 0.176 |
| Yes | 48 (17.7 %) | 30 (13.3 %) | ||
| LN metastasis | ||||
| No | 154 (57.7 %) | 148 (67.6 %) | 5.014 | 0.025 |
| Yes | 113 (42.3 %) | 71 (32.4 %) | ||
| Unknown | 4 | 7 | ||
| Histologic grade | ||||
| ≤II | 187 (70.8 %) | 165 (74.7 %) | 0.885 | 0.347 |
| >II | 77 (29.2 %) | 56 (25.3 %) | ||
| Unknown | 7 | 5 | ||
| Clinical stage | ||||
| I | 95 (35.1 %) | 100 (44.2 %) | 6.937 | 0.031 |
| II | 116 (42.8 %) | 94 (41.6 %) | ||
| III | 60 (22.1 %) | 32 (14.2 %) | ||
| ER | ||||
| (−) | 78 (29.2 %) | 56 (26.9 %) | 0.303 | 0.582 |
| (+) | 189 (70.8 %) | 152 (73.1 %) | ||
| Unknown | 4 | 18 | ||
| HER-2 | ||||
| (−) | 98 (40.3 %) | 79 (39.7 %) | 0.018 | 0.893 |
| (+) | 145 (59.7 %) | 120 (60.3 %) | ||
| Unknown | 28 | 27 | ||
| Tumor type | ||||
| IDCb | 231 (85.2 %) | 192 (85.0 %) | 0.008 | 0.929 |
| Non-IDCc | 40 (14.8 %) | 34 (15.0 %) | ||
| TGF-β | ||||
| (−) | 116 (42.8 %) | 107 (47.3 %) | 1.027 | 0.311 |
| (+) | 155 (57.2 %) | 119 (52.7 %) |
askin involvement: edema, redness, nodularity, or ulceration
bIDC, invasive ductal carcinoma
cNon-IDC: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma